Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria, GFR, and blood pressure can guide individualized treatment strategies. Emphasis is placed on explaining diagnostic findings such as the Oxford MEST-C score, monitoring disease progression, and evaluating emerging therapeutic options, including SGLT2 inhibitors, RAS blockade, budesonide, and sparsentan. Considerations around lifestyle, medication adherence, side effects, and life planning—such as employment and family planning—are explored. This dialogue-driven format demonstrates how collaborative care supports sustainable treatment adherence and improves patient engagement.